MapLight’s $251m IPO sees schizophrenia drug developers on top
MapLight’s public listing follows peer schizophrenia specialist LB Pharma’s $285m IPO last month.
Investment
Bill Gates pledges $912m to combat infectious diseases amid US funding cuts
GSK plans $30bn investment for R&D in US
LB Pharmaceuticals tops 2025 biotech IPO list with $285m Nasdaq debut
UK pharma industry risks losing world-leading status as investment plummets
WHO secures 20% funding increase amid US shortfall
Sanofi commits ‘at least $20bn’ to US manufacturing through 2030
VC firm Vivo Capital outlays $740m for biotech investment
